Dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
First-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) and who do not have EGFR mutant or ALK-positive NSCLC
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.
Project details
- Project no.
- A21-69
- Commission
- Commission awarded on 21.05.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 2.0 of the dossier Assessment replaces version 1.0 published on 2021-09-01.
Connected Projects
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed
-
Dossier assessment
Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Addendum
Atezolizumab (NSCLC; first line) - Addendum to Commission A21-69
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Status: Commission completed